Campylobacteriosis is a communicable disease resulting from the infection from the Campylobacter germ. Our firm is at the cutting edge in the research of campylobacteriosis drug and therapy development due to its proficiency in diagnosing infectious diseases, vaccine designing, and therapy devising.
Overview of Campylobacteriosis
Campylobacteriosis can be described as an inflammatory infection of the gastrointestinal tract and is mainly due to the consumption of contaminated food sources such as poultry products, unpasteurized milk, and contaminated water. A person may take from 1 to 7 days to recover from the symptoms which may include diarrhea, fever, stomach ache and vomiting. Its adverse form might lead to occurrences of Guillain-Barré syndrome which is a very uncommon form of neuron disorder.
Fig. 1 Pathways of Campylobacter transmission in both Humans and animals. (Amin S. Q., et al., 2023)
Vaccine Development for Campylobacteriosis
The most effective way to prevent an outbreak of Campylobacteriosis is the production of a suitable vaccine. The task, however, poses serious complications, owing to the nature of Campylobacter morphing into a commensal organism as well as the high genetic and antigenic diversity among different strains of the bacteria.
In one study, non-productive results were found on the part of the whole cell Campylobacter whose strains had been exposed to gamma irradiation, with the finding of an irregular immune response as a result, which was only able to save a fraction of the target population from the bacteria .
Another approach is based on CDC's pinpoint identification and selection of specific immunogenic proteins, for instance flagellar proteins and outer membrane proteins which are to be used in a subunit vaccine, while these subunit vaccines lessen the chances of catastrophic mishaps and offer targeted profile responses.
Therapeutics Development for Campylobacteriosis
Anti-Microbial Therapy
Designed for C. jejuni bacterial species, antimicrobial treatment zeroes in on certain agents capable of making a difference. Researchers have analyzed multiple avenues for immunization and noticed an intriguing one – enzymes that assist in constructing crucial bacterial building blocks like peptidoglycan and lipopolysaccharide. If such enzymes could be inhibited, the bacterial replication and existence premise could be disturbed, which sets a good stage for treatment recommendations.
Anti-Inflammatory Therapy
Being etiological factors for developing serious symptoms and post-infectious issues, the inflammatory response which has been instigated by C. jejuni infection is of great concern. Anti-Inflammatory therapy seems to have the potential of tampering with this response in some ways offering a chance of minimizing tissue damage while also improving recovery aspects. Among the declared certain targets include toll like receptors, and lipooligosaccharide, which are involved in the immunopathogenesis of Campylobacteriosis.
Our Services
We develop a wide variety of our clients' required Campylobacteriosis research activities. Our firm is engaged in infectious disease diagnosis and vaccine development, for developing the Campylobacteriosis vaccine. Our specialists apply different methods always performing thorough preclinical analysis of vaccine candidates' safety and efficacy.
Additionally, we excel in Campylobacteriosis therapy development, focusing on the identification and evaluation of potential drug candidates. Through our state-of-the-art facilities and cutting-edge technologies, we perform in vitro and in vivo studies to assess the therapeutic potential of various compounds and extracts.
Furthermore, we provide Campylobacteriosis animal models and in vitro models for research purposes. These models enable researchers to study the pathogenesis of Campylobacteriosis, evaluate the efficacy of potential therapies, and gain insights into host-pathogen interactions.
Infectious Disease Models
- Standard Mouse Infection
- SIGIRR-Deficient Mouse Infection
- IL-10-Deficient Mouse Infection
- Piglet Infection
- Ferret Infection
Through our comprehensive services, we strive to contribute to the development of safe and effective vaccines, innovative therapies, and reliable animal and in vitro models for Campylobacteriosis therapy research. If our services have piqued your interest, we warmly welcome you to reach out to us for further information and obtain a detailed quotation for the services you require.
References
- Amin S. Q., H. J. Mahmood, and H. K. Zorab. "Campylobacteriosis." One Health Triad 2 (2023): 87-93.
- Zhang Qijing, and Orhan Sahin. "Campylobacteriosis." Diseases of poultry (2020): 754-769.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
